XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial

XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial

We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced colorectal cancer (CRC). We hypothesized that this regimen would modulate soluble and cellular immune med...

Full description

Saved in:
Bibliographic Details
Main Authors: Maggie J. Phillips, Olatunji B. Alese, Natalie K. Horvat, Emily Greene, Olumide B. Gbolahan, Kathleen Coleman, Deon B. Doxie, Vaunita Parihar, Zaid K. Mahdi, Ashley McCook-Veal, Jeffrey M. Switchenko, Maria Diab, Cameron J. Herting, Chrystal M. Paulos, Bassel F. El-Rayes, Gregory B. Lesinski
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Clinical trial
colorectal cancer
cytokines
heat shock protein
immune checkpoint inhibitors
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2475620
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2475620

Similar Items